Three Works Focus on Fast & Slow Progressors and Interventions for Chinese Myopes
SAN RAMON, CALIF., March 30, 2023—As part of its multifaceted leadership in helping more eye care professionals (ECPs) embrace myopia management, CooperVision is sharing insights from three new research projects supported by the company. One explores myopia rates in fast and slow progressors, while two others concentrate on optical interventions for residents of China with myopia. All were presented as scientific posters at the 2023 Global Specialty Lens Symposium (GSLS).
“Our findings play a role in further advancing myopia control and management across the entire global eye care community,” said Elizabeth Lumb, BSc (Hons) MCOptom, FBCLA, Director of Global Professional Affairs, Myopia Management, CooperVision. “Comprehensive, trusted, and appropriately diverse research like this is crucial as the industry and professionals work together to make myopia management the standard of care in practice.”
Dual Focus Contact Lens Successfully Slows Myopia Progression in Both Fast and Slow Progressors (Kwan J., et al)1 compared eye growth rates prior to and during myopia control treatment with the CooperVision MiSight® 1 day contact lens, applying data from the company’s multi-year, international MiSight® 1 day clinical trial. Faster growing eyes wearing single vision contact lenses during the first three years of the study slowed the most when they were moved into the MiSight® 1 day treatment lens. Slower growing eyes during pre-treatment effectively stopped progressing, which means that both fast and slow progressors benefit from MiSight® 1 day contact lenses for myopia management.
As the incidence of myopia in Chinese children is among the highest of any cultural group or ethnicity2, CooperVision is ensuring that a portion of its myopia research is devoted to this area. MiSight® 1 day is the first and only soft contact lens approved* by the U.S. FDA and China NMPA to slow the progression of myopia in age-appropriate children.”3†
Short-Term Clinical and Visual Performance of Dual-focus Soft Contact Lenses in Chinese Children (Chen S, et al.)4 investigated the clinical and visual performance of MiSight® 1 day throughout one month of daily wear. Researchers evaluated 36 children ages 8-12 in the Guangzhou area who used the lenses on average for 12 hours per day, six days per week. They demonstrated wearing schedule compliance and successful independent handling at one week and one month. The children reported good visual performance (comparable distance and near high contrast visual acuity at one week versus a single vision lens) and improved overall satisfaction over one week and one month of wear.
The Effect of an Overnight Corneal Refractive Therapy Lens on Vision and Corneal Curvature in Chinese Myopes (Jiang J, et al)5 focused on adult and child myopes in China, further validating the effectiveness of reducing myopia using CooperVision’s Paragon® CRT 100 orthokeratology
lens, which has been widely fitted there since 2017. The 12-month, four-site study enrolled 254 subjects ages 8 to 43 with both eyes having myopic refractive error of -4.00DS or less, astigmatism of 1.50DC or less, and no corneal abnormalities. The Paragon CRT® 100 ortho-k lens was found to temporarily reduce myopia effectively in a large majority of Chinese patients, demonstrating significant improvements to clinically relevant levels of both uncorrected distance visual acuity and manifest refraction spherical equivalent. Significant levels of improvement were observed in both uncorrected distance visual acuity (UDVA) and low levels of myopia (MRSE) after one week, and were sustained throughout the follow-up period.
The studies represent the latest initiatives by CooperVision, a global leader in myopia control and management, to advance evidence-based practice worldwide. To read these poster presentations in their entirety, please visit https://na.eventscloud.com/website/35541/2023-posters/.
# # #
*U.S. Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
China Indications for Use: MiSight® 1 day is indicated for the correction of myopia for patients with non-diseased phakic eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 D to -4.00 D with ≤ 0.75 diopters of astigmatism. It has the dual focal design with alternative multiple rings, which allows part of the light passing through the optical zone to focus in front of the retina, forming myopic defocus with the expectation to slow the change of axial length of the patients. Fitting and evaluation of the product should be in medical institutions by ophthalmologists with an intermediate title or above and with regular monitoring. It must be used in strict accordance with the IFU requirements.
† Compared to a single vision 1-day lens over a 3-year period.
1 Kwan, et al. Dual focus contact lens successfully slows myopia progression in both fast and slow progressors. Poster presentation at the Global Specialty Lens Symposium, January 2023.
2 Wang SK, Guo Y, Liao C, et al. Incidence of and Factors Associated With Myopia and High Myopia in Chinese Children, Based on Refraction Without Cycloplegia. JAMA Ophthalmol 2016;136(9): 1017-1024
3 Chamberlain P, Peixoto-de-Matos SC, Logan NS, Ngo C, Jones D, Young G. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. Optom Vis Sci. 2019 Aug;96(8):556-567.
4 Chen S, et al. Short-Term Clinical and Visual Performance of Dual-focus Soft Contact Lenses in Chinese Children. Poster presentation at the Global Specialty Lens Symposium, January 2023.
5 Jiang J, et al. The Effect of an Overnight Corneal Refractive Therapy Lens on Vision and Corneal Curvature in Chinese Myopes. Poster presentation at the Global Specialty Lens Symposium, January 2023.
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of roughly 14,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Maggie O’Donoghue, Counselor, McDougall Communications
email@example.com or +1-585-434-2149